No Data
Express News | HOOKIPA Pharma Inc - HOOKIPA Achieves a $5 Mln Non-Dilutive Milestone Payment Under Its Collaboration and License Agreement With Gilead
Express News | HOOKIPA Pharma Announces First Person Dosed in Phase 1B Clinical Trial of Hb-500 for the Treatment of Hiv
Investors Don't See Light At End Of HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Tunnel And Push Stock Down 25%
Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
HOOKIPA Pharma Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co.: Maintains a buy rating on hookipa pharma (HOOK.US), adjusted from buy to buy rating, with a target price of $6.00, adjusted from $5.00.